Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after a rival's setback.
The 3 Things That Matter for Viking Therapeutics Now Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.
Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (
NYSE: LLY ) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98 billion to $100 billion from its market capitalization. The significant sell-off was triggered by the release of disappointing clinical trial data
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (
NYSE: LLY ) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.
Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise.
Is It Time to Buy Biotech Stocks? A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?
This Biotech Stock Could Soar on Upcoming Clinical Data This weight loss drugmaker may be significantly undervalued right now.
2 Beaten-Down Stocks With Incredible Upside Potential Getting in on the ground floor with these companies might lead to superior returns.
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the second quarter.
Viking Therapeutics Inc (NASDAQ:VKTX) Posts Wider Q2 2025 Loss, Shares Drop in After-Hours Trading Viking Therapeutics reports wider Q2 2025 loss, missing EPS estimates, causing a 5.7% after-hours dip. Focus remains on clinical pipeline progress amid revenue challenges.
